ACCESS REALMONEY
Email This Article
FDA Panel Rejects Cephalon's Sparlon
By
Robert Steyer
03/23/06 - 07:28 PM EST
The company is dealt a serious blow as experts say the ADHD drug poses too many risks.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
Sign up for our FREE newsletters now.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
